Metformin Add-on Clinical Study in Multiple Sclerosis to Evaluate Brain Remyelination And Neurodegeneration

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

November 23, 2023

Primary Completion Date

February 28, 2027

Study Completion Date

February 28, 2027

Conditions
Multiple SclerosisPrimary Progressive Multiple SclerosisSecondary-progressive Multiple Sclerosis
Interventions
DRUG

Metformin Hydrochloride 850 mg Oral Tablet

Metformin Hydrochloride oral tablets 850 mg t.i.d. or b.i.d.

DRUG

Placebo

Placebo matching Metformin Hydrochloride oral tablets t.i.d. or b.i.d.

Trial Locations (5)

Unknown

AZ Sint-Jan Brugge, Bruges

Antwerp University Hospital, Edegem

University Hospital Ghent, Ghent

National MS Center Melsbroek, Melsbroek

Noorderhart, Overpelt

All Listed Sponsors
collaborator

University Hospital, Ghent

OTHER

collaborator

Hasselt University

OTHER

collaborator

AZ Sint-Jan AV

OTHER

collaborator

Noorderhart Pelt

OTHER

collaborator

National MS Center Melsbroek

OTHER

lead

University Hospital, Antwerp

OTHER

NCT05893225 - Metformin Add-on Clinical Study in Multiple Sclerosis to Evaluate Brain Remyelination And Neurodegeneration | Biotech Hunter | Biotech Hunter